About Beam Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://beamtx.com/
Frequently Asked Questions
What is the 52-week range for BEAM?
The 52-week high is $38.26 and the 52-week low is $20.23.
What is the P/E ratio for BEAM?
The P/E ratio data is currently unavailable.
What is the dividend yield for BEAM?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -7.70%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -54.75%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 2.27.
Analyst Recommendation Trends
Wall Street analyst consensus for BEAM over the last few months:
Latest BEAM News
Will IP Theft Allegations Against YolTech and Serapha Bio Change Beam Therapeutics' (BEAM) Narrative
In September 2026, Beam Therapeutics filed a lawsuit alleging that former scientist Zi Jun “Emma” Wang stole confidential research to co-found Chinese biotech YolTech Therapeutics and, through it, helped create Serapha Bio using Beam’s trade secrets and patentable know‑how. This dispute underscores intensifying concerns over intellectual property protection and cross‑border competition in gene editing, particularly between U.S. and Chinese biotech companies. We’ll now examine how this...
Beam sues 2 biotechs, alleging theft of base editing trade secrets
Beam claimed a former scientist stole confidential information and quietly spun up a rival rare disease treatment at YolTech Therapeutics. Serapha Bio, which licensed that therapy, denies the charges.
Temporary Weakness in Intellia Stock Seems Like a Buying Opportunity
Here's how to play leading gene-editing stocks as Anthropic's AI tools make progress in the gene-editing space.
Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical Progress
Beam Therapeutics (BEAM) stock analysis: BEAM-302 gene-editing upside for 2028â2029, cash runway/dilution risks, valuation vs peersâread now.
As Claude Enters the Gene-Editing Arena, There’s Still a Long-Term Case for BEAM Stock
Anthropic says Claude found a new enzyme system that resembles CRISPR. Here is what it means for Beam Therapeutics and whether BEAM stock looks like a buy.
Cathie Wood Makes $64 Million Bet on Two Stocks
The latest trades reveal where Wood sees opportunity
Prime: A Buy Due To BLA Filing H1 '27 And Continued PM647 Advancement
Prime Medicine, Inc. maintains a Buy rating, supported by an advancing prime editing pipeline and multiple upcoming clinical catalysts. Click for a PRME update.
Squeeze Watch: 10 Stocks With Over 33% Short Interest
Ten stocks have over 34% of their float short, with ONDS and BROS on the list led by VG.
Anthropic AI Discovery Gene-Editing Stocks Falling
Anthropic says Claude identified a novel enzyme system with characteristics reminiscent of CRISPR
Beam Therapeutics (BEAM) Stock Could Trade At A Premium As Gene Editing Interest Grows
Beam Therapeutics sits in a crowded gene editing field, and its share price history raises a simple question for you as an investor: Is the current US$24.37 price properly reflecting what the business is generating in sales today? Over the past 5 years the stock has fallen 72.1%, which puts the focus squarely on whether the revenue it produces can still justify even the current market value. Recent coverage of the in vivo gene editing market highlights Beam Therapeutics as a key participant...
CRISPR Therapeutics Traded Sideways and Down for 12 Months: One Wall Street Pro Expects 85% Gains Soon
CRISPR Therapeutics owns the only approved gene therapy of its kind, yet the stock sits far below where Wall Street thinks it belongs. One analyst sees a path to gains that would embarrass the broader market, but the numbers tell a complicated story.
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The widely followed growth investor keeps making moves.
Beyond Meta, Cathie Wood’s ARKG Loads Up On These 4 Biotech Names
ARK’s latest portfolio moves spotlighted IONS, VCYT, SCTX, and BEAM as the firm increased its biotech exposure alongside a major Meta purchase.
Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets
Cathie Wood’s ARKG bought Ionis, Beam, Veracyte and Scribe Therapeutics. Here are the biotech ETFs that also hold her latest bets.
In Vivo Gene Editing Market Size, Share & Trends Analysis - Global Opportunity Analysis & Industry Forecast (2026-2036)
The global in vivo gene editing market was valued at USD 3.4 billion in 2025 and is forecast to reach USD 22.6 billion by 2036, growing at a 16.8% CAGR from 2026. Growth is driven by CRISPR, base and prime editing, LNP and AAV delivery systems, precision medicine investment, and expanding clinical pipelines for genetic disorders, oncology, cardiovascular and neurological diseases. North America leads the market, while Asia-Pacific is expected to grow fastest. Key players include CRISPR Therapeut
Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry?
NTLA wins FDA priority review for lonvo-z, with a March 10, 2027 decision, potentially adding its first product, while nex-z studies are progressing well.
Gene-Editing Powerhouse And Its Rivals Surge Toward A Breakout
Crispr stock, alongside other gene-editing equities, pulled a bullish move Thursday — bounding for a breakout from a cup-with-handle base.
These 10 Stocks Are Squeeze Candidates Waiting to Happen
These 10 heavily shorted stocks face potential reversals, led by Venture Global, followed by CleanSpark and Dutch Bros.
Beam Therapeutics: Market Selling Phase 2 AATD Data Is Understandable, In My View
Beam Therapeutics' BEAM-302 Phase 1/2 AATD results show sustained AAT increases, but durability, safety, and approval risks remain. Click for this BEAM update
Beam Therapeutics (BEAM) Restored AAT Levels. Can BEAM-302 Deliver Clinical Benefit?
Beam Therapeutics Inc. (NASDAQ:BEAM) reported updated Phase 1/2 results on September 8 for BEAM-302, an investigational gene-editing treatment for alpha-1 antitrypsin deficiency, or AATD. Although 38 patients had been treated by August 17, the presented efficacy analysis covered 29 single-dose patients at the June 24 cutoff. Biomarker results extended to 18 months, while overall patient […]
Beam Therapeutics Inc. (BEAM) Discusses Updated Phase 1/2 Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency - Slideshow
2026-09-10. The following slide deck was published by Beam Therapeutics Inc.
Beam Therapeutics Inc. (BEAM) Presents at European Respiratory Society (ERS) Congress - Slideshow
2026-09-10. The following slide deck was published by Beam Therapeutics Inc.
Beam Therapeutics Inc. (BEAM) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Beam Therapeutics Inc. (BEAM) Citigroup's Biopharma Back to School Summit 2026 September 9, 2026 1:00 PM EDTCompany ParticipantsSravan Emany - Chief...
Wedbush Reiterates Outperform on Beam Therapeutics, Maintains $65 Price Target
Wedbush analyst David Nierengarten reiterates Beam Therapeutics (NASDAQ:BEAM) with a Outperform and maintains $65 price target.
3 Promising Genomics Stocks in the Spotlight in 2026
Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicine.
Beam Therapeutics Targets Accelerated FDA Approval for Base-Editing Treatment
Beam Therapeutics Inc. (NASDAQ:BEAM) on Tuesday presented updated Phase 1/2 trial data for BEAM-302, an experimental base-editing therapy for alpha-1 antitrypsin deficiency (AATD). AATD is a hereditary disorder caused by low levels of protective AAT protein, leading to lung damage (emphysema, COPD) and liver disease. The company shared these findings at the European Respiratory Society Congress 2026, showcasing the genetic medicine’s potential to directly correct the root cause of both liver and
Beam Therapeutics Inc. (BEAM) Discusses Updated Phase 1/2 Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency Transcript
Beam Therapeutics Inc. (BEAM) Discusses Updated Phase 1/2 Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency September 8, 2026 7:00 AM EDTCompany...
Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026
BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months Follow-Up, Data Show Long-Term Durability of In Vivo Correction of Disease-causing Mutation with Single Dose of BEAM-302 Treatment with BEAM-302 Increased Total and Functional AAT and Decreased Neutrophil Elastase Activity in Circulation BEAM-302 Led to Reduction in Circulating Mutant Z-AAT and Corres
Beam Therapeutics Announces Updated Clinical Data From Its Phase 1/2 Trial Evaluating BEAM-302 For Alpha-1 Antitrypsin Deficiency; BEAM-302 Continues To Demonstrate Potential As One-Time Treatment For Both Lung And Liver Manifestations Of AATD
With Up to 18 Months Follow-Up, Data Show Long-Term Durability of In Vivo Correction of Disease-causing Mutation with Single Dose of BEAM-302Treatment with BEAM-302 Increased Total and Functional AAT and Decreased
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-24 | Ciaramella Giuseppe | -123,407 | - | - |
| 2026-07-27 | Simon Amy | -16,667 | $25.7417 | $429,037 |
| 2026-06-30 | Simon Amy | -373 | $34.73 | $12,954 |
| 2026-06-30 | Evans John M. | -25,000 | - | - |
| 2026-06-30 | Evans John M. | -1,900 | $34.8437 | $66,203 |
| 2026-06-30 | Evans John M. | -23,100 | $34.2633 | $791,482 |
| 2026-06-30 | Evans John M. | +25,000 | $1.03 | $25,750 |
| 2026-06-29 | Evans John M. | -6,337 | - | - |
| 2026-06-29 | Evans John M. | -18,663 | - | - |
| 2026-06-29 | Evans John M. | -11,579 | $35.9119 | $415,824 |
| 2026-06-29 | Evans John M. | -13,421 | $35.1336 | $471,528 |
| 2026-06-29 | Evans John M. | +6,337 | $1.03 | $6,527 |
| 2026-06-29 | Evans John M. | +18,663 | $0.67 | $12,504 |
| 2026-06-17 | Ciaramella Giuseppe | -29,000 | - | - |
| 2026-06-17 | Ciaramella Giuseppe | -6,505 | - | - |
| 2026-06-17 | Ciaramella Giuseppe | +29,000 | $1.03 | $29,870 |
| 2026-06-17 | Ciaramella Giuseppe | +6,505 | $0.67 | $4,358 |
| 2026-06-03 | Fishman Mark | +19,676 | - | - |
| 2026-06-03 | Guindo Chirfi | +19,676 | - | - |
| 2026-06-03 | Shaw Christi | +19,676 | - | - |
| 2026-06-03 | Walsh Kathleen E | +19,676 | - | - |
| 2026-06-03 | COOPER GRAHAM K | +19,676 | - | - |
| 2026-06-03 | MARAGANORE JOHN | +19,676 | - | - |
| 2026-04-01 | Evans John M. | -30,078 | $24.58 | $739,317 |
| 2026-04-01 | Simon Amy | -6,700 | $24.58 | $164,686 |
| 2026-04-01 | Cavanagh Bethany J | -3,242 | $24.58 | $79,688 |
| 2026-04-01 | Bellon Christine | -5,956 | $24.58 | $146,398 |
| 2026-04-01 | Ciaramella Giuseppe | -11,810 | $24.58 | $290,290 |
| 2026-03-31 | Bellon Christine | +20,000 | - | - |
| 2026-03-31 | Cavanagh Bethany J | +20,000 | - | - |
| 2026-03-31 | Simon Amy | +31,750 | - | - |
| 2026-03-31 | Emany Sravan Kumar | +31,750 | - | - |
| 2026-03-31 | Ciaramella Giuseppe | +40,000 | - | - |
| 2026-03-31 | Evans John M. | -25,000 | - | - |
| 2026-03-31 | Evans John M. | +90,000 | - | - |
| 2026-03-31 | Evans John M. | -25,000 | $22.7634 | $569,085 |
| 2026-03-31 | Evans John M. | +25,000 | $0.67 | $16,750 |
| 2026-03-30 | Evans John M. | -25,000 | - | - |
| 2026-03-30 | Evans John M. | -25,000 | $22.3692 | $559,230 |
| 2026-03-30 | Evans John M. | +25,000 | $0.67 | $16,750 |
| 2026-02-24 | Ciaramella Giuseppe | -35,000 | - | - |
| 2026-02-24 | Ciaramella Giuseppe | -35,000 | $32.0012 | $1,120,042 |
| 2026-02-24 | Ciaramella Giuseppe | +35,000 | $17 | $595,000 |
| 2026-01-31 | Ciaramella Giuseppe | +80,000 | - | - |
| 2026-01-31 | Cavanagh Bethany J | +40,000 | - | - |
| 2026-01-31 | Emany Sravan Kumar | +63,500 | - | - |
| 2026-01-31 | Bellon Christine | +40,000 | - | - |
| 2026-01-31 | Evans John M. | +180,000 | - | - |
| 2026-01-31 | Simon Amy | +88,500 | - | - |
| 2026-01-30 | Evans John M. | -25,000 | - | - |
| 2026-01-30 | Evans John M. | -2,906 | $29 | $84,274 |
| 2026-01-30 | Evans John M. | -22,094 | $28.2734 | $624,672 |
| 2026-01-30 | Evans John M. | +25,000 | $0.67 | $16,750 |
| 2026-01-29 | Evans John M. | -5,664 | - | - |
| 2026-01-29 | Evans John M. | -19,336 | - | - |
| 2026-01-29 | Evans John M. | -8,667 | $29.7428 | $257,781 |
| 2026-01-29 | Evans John M. | -16,333 | $29.1925 | $476,801 |
| 2026-01-29 | Evans John M. | +5,664 | $0.67 | $3,795 |
| 2026-01-29 | Evans John M. | +19,336 | $0.67 | $12,955 |
| 2026-01-22 | Cavanagh Bethany J | -6,198 | $35.0005 | $216,933 |
| 2026-01-22 | Bellon Christine | -1,371 | $34 | $46,614 |
| 2026-01-20 | Cavanagh Bethany J | -3,034 | $30.12 | $91,384 |
| 2026-01-15 | Bellon Christine | -559 | $35.3988 | $19,788 |
| 2026-01-15 | Bellon Christine | -15,959 | $34.7182 | $554,068 |
| 2026-01-15 | Bellon Christine | -2,111 | $33.6219 | $70,976 |
| 2025-12-31 | Emany Sravan Kumar | -6,294 | $27.1 | $170,567 |
| 2025-12-31 | Bellon Christine | -1,254 | $27.1 | $33,983 |
| 2025-12-31 | Simon Amy | +12,500 | - | - |
| 2025-10-27 | FMR LLC | -459 | $26.68 | $12,246 |
| 2025-10-06 | FMR LLC | -1,232,434 | - | - |